subslover
12 months ago
SenesTech Announces Development and Distribution Agreement for ContraPest® in South Africa
PHOENIX, June 1, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, announced entry into a Development and Distribution Agreement with Pathogens and Environmental Solutions (PES) of South Africa for the commercialization of ContraPest® into South Africa. Under the agreement, PES will be responsible for seeking regulatory registration, and all marketing and sales of ContraPest into South Africa.
"South Africa is a leading sub-Saharan economy with an active pest control industry focused on the agricultural and public health applications of pest control. We were introduced to South Africa and PES by the South African National Council of SPCAs (NSPCA), who are continuing to advise us, and who clearly articulated their support for fertility control and ContraPest in particular. They have committed to recommend ContraPest to private and state entities and to assist with regulatory issues," said Joel Fruendt, SenesTech's President and CEO.
"NSPCA brought in PES as being an excellent partner for us in this project, as they have extensive experience in securing registration and launching commercialization of pest control products. Specifically, PES is a leading manufacturer and distributor of rodent pest control products, with an explicit goal to constantly grow their range of products by adding innovative products for integrated pest management (IPM)," continued Mr. Fruendt. "While we are starting in South Africa, I have no doubt that we will be able to expand our work with PES across its sub-Saharan territories."
"At PES we aim to bring innovative products to the African Sub-Saharan region. Contrapest fits this aim perfectly, and partnering with Senestech was a logical fit for us at PES, as we are always looking for industry leading products," said Reon Hillebrand, Director at PES. "Once regulatory approval is achieved, we look forward to offering our customers this unique rodent control alternative, complementing our current rodent control offering in South Africa and our other African partners."
About SenesTech
We are the experts in rat fertility control. Our passion is to create a healthy environment by better controlling rat pest populations. We keep an inescapable truth in mind. Two rats and their descendants can be responsible for the birth of up to 15,000 pups after a year. We invented ContraPest, the only U.S. EPA registered contraceptive for male and female rats. ContraPest fits seamlessly into all integrated pest management programs, greatly improving the overall goal of effective rat management. We strive for clean cities, efficient businesses, and happy households – with a product that was designed to be effective and sustainable without killing rats. At SenesTech, we are committed to improving the
leemalone2k3
2 years ago
My favorite long term hold.
Holding 2024 2.00 calls at .30
Holding stock at 1.83, selling covered calls against them on pops.
Senseonics Holdings' Elevance Diabetes System Secures Coverage Under Elevance Health; Shares Rise
8/3/22, 11:18 AM
11:18 AM EDT, 08/03/2022 (MT Newswires) -- Senseonics Holdings (SENS) said Wednesday that US insurance company Elevance Health has agreed to provide coverage for the Eversense continuous glucose monitoring system.
The device is designed to continually measure glucose levels in people aged 18 and over with diabetes for up to six months. It is meant to replace fingerstick blood glucose measurements for diabetes treatment decisions.
With the Elevance Health coverage, over 45 million people across 14 states would be able to add the Eversense system to their health plans, Senseonics said.
Shares of the medical technology company were up more than 16% in recent trading activity.
nbm16yankees
2 years ago
thanks for responding.
What you say makes a lot of sense.
I'm just feeling my way with PUTS, as I have not written too many.
I usually sell covered calls and have enjoyed much success.
But my reasoning for going out so long, is I believe SENS will do well in 6-9 months. So if they put the stock to me at $1.50 then I am using my money for other ventures. I like the company very much,
but their guidance IMO, tells me we need to be patient.
So, my next question to you regards what happens to the put if there is a buyout at say 5 or 6 dollars +/- ? Does the price drop accordingly and gives me the chance to buy it back at much cheaper price, or do they put it to me at $1.50?
Much thanks for your input and education.
nbm16yankees
2 years ago
Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for March 1, 2022, at 4:30 p.m. Eastern Time
February 15, 2022
GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2021 financial results after market close on Tuesday, March 1, 2022.
Management will hold a conference call to review the Company’s fourth quarter and full year 2021 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International), passcode 2775821, approximately ten to five minutes prior to start time.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems, Eversense®, Eversense® XL and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220215006052/en/
Senseonics Investor Contact
Lynn Lewis or Philip Taylor
Investor Relations
415-937-5406
investors@senseonics.com
Source: Senseonics Holdings, Inc.
<< Back to 2022 News Releases
nbm16yankees
2 years ago
Ascensia issues positive PR
ASCENSIA DIABETES CARE ANNOUNCES FDA APPROVAL OF THE EVERSENSE E3 CONTINUOUS GLUCOSE MONITORING SYSTEM FOR USE FOR UP TO 6 MONTHS
February 14 2022 - 07:00AM
PR Newswire (US)
PARSIPPANY, N.J., Feb. 14, 2022 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, announces that its partner Senseonics Holdings, Inc. (NYSE American: SENS) has received approval from the U.S. Food and Drug Administration (FDA) for the next-generation Eversense® E3 Continuous Glucose Monitoring (CGM) System. Ascensia plans to make the Eversense E3 sensor, which can be used for up to 6 months, available to patients in the U.S. during the second quarter of 2022.
Ascensia Diabetes Care logo
Robert Schumm, President at Ascensia Diabetes Care, said, "As the world's first and only long-term CGM System, Eversense is truly innovative and the prospect of using a single sensor for 6 months is a huge step forward for people with diabetes. Ensuring that as many people as possible have access to Eversense E3 is key for us and we'll be introducing a program to help users experience Eversense affordably as we work closely with payers on coverage. We look forward to rolling out this next-generation system through our dedicated CGM commercial team in the U.S. in the coming months, as we strive to improve the lives of people with diabetes everywhere."
Developed by Senseonics and brought to people with diabetes by Ascensia, the newly approved Eversense E3 CGM System, which includes a sacrificial boronic acid (SBA) design modification to enhance sensor survival, offers patients:
The longest lasting CGM available, with 6-month sensor wear duration and essentially two sensor insertion and removal procedures per year
Exceptional accuracy, with a mean absolute relative difference (MARD) of 8.5% demonstrated in the PROMISE Study1 for the duration of sensor wear
A fully implantable fluorescence-based sensor, with a removable smart transmitter* that provides discreet on-body vibratory alerts and transmits data to a mobile app
Fewer calibrations, with primarily one calibration required per day after day 21 of use
"This next generation system delivers on the patient's desire for a CGM sensor that is both long-lasting and highly accurate," said Elaine Anderson, Head of Eversense CGM Business Unit at Ascensia Diabetes Care. "Its unique features and benefits offer people with diabetes unparalleled flexibility, convenience and accuracy. Our partner Senseonics has designed Eversense E3 with the user in mind and we are excited to bring the system to people in the U.S. in the second quarter."
To be among the first to know when Eversense E3 is commercially available, patients who are interested in getting started with Eversense now can sign up at www.eversensediabetes.com/get-started-today. Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense CGM System can sign up at www.ascensiadiabetes.com/eversense/become-a-provider/register/. Alternatively, contact 844-SENSE4U (844-736-7348) to learn more about the first and only long-term implantable CGM system.
* There is no glucose data generated when the transmitter is removed.
1 Garg S. et al. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics 2021; 24(2): 1-9.DOI: 10.1089/dia.2021.0182
View original content:https://www.prnewswire.com/news-releases/ascensia-diabetes-care-announces-fda-approval-of-the-eversense-e3-continuous-glucose-monitoring-system-for-use-for-up-to-6-months-301481042.html
SOURCE Ascensia Diabetes Care
Copyright 2022 PR Newswire